Most study groups have employed the human breast cancer cell lines MCF-7 and MDA-MB-231 and discovered that the bitter melon extract might efficiently inhibit the in vitro progression of both estrogen receptor-positive and estrogen receptor-negative breast cancer cells. Here, ESR1 is linked to breast carcinoma.